×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACAD – acadia pharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACAD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/14
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/13
04:05 pm
acad
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Medium
Report
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
3/8
02:05 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/7
12:32 pm
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $20.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $20.00 price target on the stock.
3/5
09:18 am
acad
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med [Yahoo! Finance]
Low
Report
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med [Yahoo! Finance]
3/5
09:05 am
acad
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Low
Report
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
3/3
09:05 am
acad
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
Medium
Report
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
2/28
11:04 pm
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2025
04:05 pm
ACAD
acadia pharmaceuticals inc.
BEAT
Report
1.8%
acadia pharmaceuticals inc.
2/26/2025
04:05 pm
ACAD
acadia pharmaceuticals inc.
BEAT
Report
1.8%
acadia pharmaceuticals inc.
2/26/2025
04:05 pm
ACAD
acadia pharmaceuticals inc.
BEAT
Report
1.8%
acadia pharmaceuticals inc.
2/26/2025
04:05 pm
ACAD
acadia pharmaceuticals inc.
BEAT
Report
1.8%
acadia pharmaceuticals inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
08:10 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Kihara James
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Kihara James
3/26
08:06 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Schneyer Mark C.
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Schneyer Mark C.
3/26
08:03 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Rhodes Jennifer J
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Rhodes Jennifer J
3/26
07:53 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Thompson Elizabeth H.Z.
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Thompson Elizabeth H.Z.
3/26
07:50 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Owen Adams Catherine
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Mar 24 Filed by: Owen Adams Catherine
3/6
06:30 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Mar 05 Filed by: GAROFALO ELIZABETH A.
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Mar 05 Filed by: GAROFALO ELIZABETH A.
3/6
12:18 pm
acad
Form 144 ACADIA PHARMACEUTICALS Filed by: GAROFALO ELIZABETH A.
Low
Report
Form 144 ACADIA PHARMACEUTICALS Filed by: GAROFALO ELIZABETH A.
2/27
05:26 pm
acad
Form 10-K ACADIA PHARMACEUTICALS For: Dec 31
Low
Report
Form 10-K ACADIA PHARMACEUTICALS For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/9
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
61.4%
7/31 Q2/2019 6/30/2019 EPS -0.380 ZacksConsensus -0.460 ActVsEst 0.080 - Beat 16.6%
12/4 Acadia Pharma's psychosis drug proven better than placebo in dementia patients [Reuters] 10.9%
11/11 ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019 9.3%
9/14 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 9.0%
10/19 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.1%
4/2 Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead [Seeking Alpha] 6.8%
5/3 ACADIA -3.5% after 40.2M-share shelf registration [Seeking Alpha] 6.7%
9/9 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Piper Jaffray Companies from $35.00 to $56.00. They now have an "overweight" rating on the stock. 6.5%
3/3 ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome 6.1%
7/31 Q2/2019 6/30/2019 EPS -0.380 ZacksConsensus -0.460 ActVsEst 0.080 - Beat 16.6%
12/4 Acadia Pharma's psychosis drug proven better than placebo in dementia patients [Reuters] 10.9%
11/11 ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019 9.3%
9/14 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 9.0%
10/19 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.1%
4/2 Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead [Seeking Alpha] 6.8%
5/3 ACADIA -3.5% after 40.2M-share shelf registration [Seeking Alpha] 6.7%
9/9 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Piper Jaffray Companies from $35.00 to $56.00. They now have an "overweight" rating on the stock. 6.5%
3/3 ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome 6.1%
TOP News Decliners
9/9
Form 8-K ACADIA PHARMACEUTICALS For: Sep 09
-22.3%
7/22 Acadia's schizophrenia treatment fails to meet main goal of late-stage study [Reuters] -14.4%
1/13 Form 8-K ACADIA PHARMACEUTICALS For: Jan 13 -9.1%
8/31 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.7%
5/1 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.4%
9/11 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was given a new $60.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -7.3%
12/6 Form 4 ACADIA PHARMACEUTICALS For: Dec 05 Filed by: DAVIS STEPHEN -6.4%
2/27 ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.3%
9/25 ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 -6.0%
3/5 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.6%
7/22 Acadia's schizophrenia treatment fails to meet main goal of late-stage study [Reuters] -14.4%
1/13 Form 8-K ACADIA PHARMACEUTICALS For: Jan 13 -9.1%
8/31 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.7%
5/1 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.4%
9/11 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was given a new $60.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -7.3%
12/6 Form 4 ACADIA PHARMACEUTICALS For: Dec 05 Filed by: DAVIS STEPHEN -6.4%
2/27 ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.3%
9/25 ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 -6.0%
3/5 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: